机构：[1]Department of Bio-therapeutic, the First Medical Center, Chinese PLA General Hospital, 100853 Beijing, China[2]Department of Oncology, the first Medical Center, Chinese PLA General Hospital, 100853 Beijing, China[3]State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu 610041, China四川大学华西医院[4]Collaborative Innovation Center for Biotherapy, Chengdu 610041, China[5]Department of Cell and Molecular Therapies, Royal Prince Alfred Hospital, Sydney, NSW 2006, Australia[6]Gene and Stem Cell Therapy Program, Centenary Institute, University of Sydney, Sydney, NSW 2006, Australia[7]Central Clinical School, Faculty of Medicine and Health, The University of Sydney, Camperdown, NSW 2050, Australia[8]Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104-515, USA[9]Department of Hematology, The Second Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou 310009, China[10]Department of Hematology, Shanghai Tongji Hospital, Tongji University School of Medicine, Shanghai 200065, China[11]State Key Laboratory of Kidney Diseases, National Clinical Research Center for Kidney Diseases, 100853 Beijing, China
Chimeric antigen receptor T (CAR T) cell therapy has demonstrated efficacy in the treatment of haematologic malignancies. However, the accompanying adverse events, the most common of which is cytokine release syndrome (CRS), substantially limit its wide application. Due to its unique physiological characteristics, CRS in CAR T-cell treatment for B-cell non-Hodgkin lymphoma (B-NHL) may exhibit some special features. Although existing guidelines had greatly promoted the recognition and management of CRS, many recommendations are not fully applicable to B-NHL. Therefore, it is imperative to identify responses that are specific to CRS observed following CAR T treatment for B-NHL. Based on underlying biological processes and known pathophysiological mechanisms, we tentatively propose a new model to illustrate the occurrence and evolution of CAR T-cell-therapy-related CRS in B-NHL. In this model, tumour burden and bone marrow suppression are considered determinants of CRS. Novel phenomena after CAR T-cell infusion (such as local inflammatory response) are further identified. The proposed model will help us better understand the basic biology of CRS and recognize and manage it more rationally.
基金：
This research was supported by grants from the National Natural Science Foundation
of China (No. 81830002 and 31991171 to W.D.H., No. 81703044 to J.S.W., No.
81830006 to W.B.Q. and No. 8183004 to A.B.L.), a Leading Talents Grant of Science &
Technology from Beijing (No. Z181100006318004 to W.D.H.) and a grant from the
Science Technology Department of Zhejiang Province (No. 2018C03016-1 to W.B.Q.). J.E.J.R. was supported by NHMRC investigator (1177305) and project (1128175)
grants; the Li Ka Shing Foundation and an anonymous foundation.
语种：
外文
PubmedID：
中科院(CAS)分区：
出版当年[2020]版：
大类|1 区医学
小类|1 区生化与分子生物学1 区细胞生物学
最新[2023]版：
大类|1 区医学
小类|1 区生化与分子生物学1 区细胞生物学
第一作者：
第一作者机构：[1]Department of Bio-therapeutic, the First Medical Center, Chinese PLA General Hospital, 100853 Beijing, China
共同第一作者：
通讯作者：
通讯机构：[1]Department of Bio-therapeutic, the First Medical Center, Chinese PLA General Hospital, 100853 Beijing, China[11]State Key Laboratory of Kidney Diseases, National Clinical Research Center for Kidney Diseases, 100853 Beijing, China
推荐引用方式(GB/T 7714)：
Wei Jianshu,Liu Yang,Wang Chunmeng,et al.The model of cytokine release syndrome in CAR T-cell treatment for B-cell non-Hodgkin lymphoma.[J].Signal transduction and targeted therapy.2020,5(1):134.doi:10.1038/s41392-020-00256-x.
APA：
Wei Jianshu,Liu Yang,Wang Chunmeng,Zhang Yajing,Tong Chuan...&Han Weidong.(2020).The model of cytokine release syndrome in CAR T-cell treatment for B-cell non-Hodgkin lymphoma..Signal transduction and targeted therapy,5,(1)
MLA：
Wei Jianshu,et al."The model of cytokine release syndrome in CAR T-cell treatment for B-cell non-Hodgkin lymphoma.".Signal transduction and targeted therapy 5..1(2020):134
医学